Phathom Pharmaceuticals, INC

Phathom Pharmaceuticals announced record Q2 2026 net revenues of $74.3 million, an 88% increase year-over-year, alongside a significant reduction in operating expenses and achievement of operating profitability excluding stock-based compensation.

Phathom Pharmaceuticals, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of Class I directors and the ratification of its independent auditor.

Phathom Pharmaceuticals reported a 104% year-over-year increase in Q1 2026 net revenues to $58.3 million, while reducing operating expenses and maintaining full-year guidance with expected operating profitability in Q3 2026.

Phathom Pharmaceuticals announced robust fourth quarter and full year 2025 financial results, driven by significant VOQUEZNA revenue growth and strategic financial restructuring, projecting operating profitability by Q3 2026.

Phathom Pharmaceuticals announced the pricing of an underwritten public offering of common stock and pre-funded warrants, aiming to raise approximately $130 million for general corporate purposes.

Phathom Pharmaceuticals announced preliminary unaudited financial results for Q4 and full year 2025, highlighting strong revenue and a milestone for VOQUEZNA.

Phathom Pharmaceuticals announced strong revenue growth in its Q2 2026 report, driven by its VOQUEZNA product line, while managing operating expenses.

Phathom Pharmaceuticals reports a significant increase in Q1 2026 revenue driven by VOQUEZNA sales, while net loss narrows compared to the prior year period.

Phathom Pharmaceuticals reports significant revenue growth and a reduced net loss in Q3 2025, driven by strong VOQUEZNA sales, while managing liquidity and strategic restructuring.

Phathom Pharmaceuticals reported significant product revenue growth for Q2 2025, driven by its VOQUEZNA franchise, while also implementing a workforce reduction to optimize commercial execution.

Phathom Pharmaceuticals reports a net loss of $94.3 million for Q1 2025 and announces a restructuring plan to reduce cash burn and focus on commercial execution.

Phathom Pharmaceuticals reported its Q3 2024 results, highlighting revenue growth from the commercial launch of Voquezna products and ongoing clinical development efforts.

Phathom Pharmaceuticals reported significant revenue growth in 2025 driven by VOQUEZNA sales, while narrowing net losses and securing new financing to support its path to operating profitability by Q3 2026.

Phathom Pharmaceuticals announces its FY2024 results, emphasizing the commercial launch and growing demand for VOQUEZNA.

Phathom Pharmaceuticals files an amendment to its 10-K report, primarily to correct certifications and provide additional details on its stock and financial structure.

Phathom Pharmaceuticals initiated the commercial launch of VOQUEZNA for Erosive GERD and H. pylori in Q4 2023, while also advancing its pipeline with a focus on Non-Erosive GERD and Eosinophilic Esophagitis.

Robert Charles Breedlove, Principal Accounting Officer of Phathom Pharmaceuticals, Inc., reported a transaction in 1,555 shares of common stock on July 14, 2026.

Phathom Pharmaceuticals Director Asit Parikh reported a transfer of 28,000 common shares to a trust for his spouse's benefit.

Director Asit Parikh acquired 24,122 restricted stock units and exercised options for 17,500 shares of Phathom Pharmaceuticals.

James N. Topper, a Director and 10% owner of Phathom Pharmaceuticals, Inc., acquired 24,122 Restricted Stock Units (RSUs) on May 19, 2026.

Phathom Pharmaceuticals, Inc. reports that Director Mark Stenhouse was granted Restricted Stock Units (RSUs) on May 19, 2026, with vesting contingent on continued service.

Heidi Fields, a Director at Phathom Pharmaceuticals, Inc., acquired 24,122 shares of common stock through Restricted Stock Units on May 19, 2026.

Phathom Pharmaceuticals details a year of leadership transition and significant commercial momentum for VOQUEZNA in its 2026 proxy statement.

Phathom Pharmaceuticals has scheduled its annual stockholder meeting for June 3, 2025, and is seeking votes on director elections, auditor ratification, executive compensation, and the frequency of say-on-pay votes.

Phathom Pharmaceuticals announces its 2025 annual meeting of stockholders to be held virtually on June 3, 2025, outlining proposals for director elections, auditor ratification, executive compensation, and voting frequency.

Phathom Pharmaceuticals announces its 2024 Annual Meeting of Stockholders to be held virtually on May 23, 2024, with voting open until May 22, 2024.

Phathom Pharmaceuticals will hold its annual stockholder meeting virtually on May 23, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Frazier Life Sciences Public Fund increases its stake in Phathom Pharmaceuticals following a merger with Frazier Life Sciences Public Overage Fund.

Frazier Life Sciences and affiliated entities filed an amended Schedule 13D, clarifying their beneficial ownership in Phathom Pharmaceuticals, Inc. and correcting prior attributions.

Frazier Life Sciences and its affiliated funds have significantly increased their beneficial ownership in Phathom Pharmaceuticals, Inc., now holding an aggregate of approximately 19.9% of the common stock.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 4.2% of Phathom Pharmaceuticals, Inc. common stock.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, reported a 5.3% beneficial ownership stake in Phathom Pharmaceuticals, Inc.

Millennium Management and affiliated entities have updated their passive beneficial ownership in Phathom Pharmaceuticals, Inc., reporting a collective stake of 2.7% as of December 31, 2025.

Millennium Management and affiliated entities have increased their beneficial ownership in Phathom Pharmaceuticals, Inc. to 7.1%.

Carlyle Group and its affiliates reported their beneficial ownership in Phathom Pharmaceuticals, Inc. has fallen to 4.9% due to dilution from the issuer's stock issuances.

Millennium Management LLC and affiliated entities have disclosed a 5.9% beneficial ownership stake in Phathom Pharmaceuticals, Inc. through a Schedule 13G filing.